US equities
|
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
META
$741.90
▲+1.90%
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
META
$741.90
▲+1.90%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by IN8bio, Inc
IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
May 09, 2024
From
IN8bio, Inc
Via
GlobeNewswire
Tickers
INAB
IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma
April 30, 2024
From
IN8bio, Inc
Via
GlobeNewswire
Tickers
INAB
IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
April 24, 2024
From
IN8bio, Inc
Via
GlobeNewswire
Tickers
INAB
IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
April 16, 2024
From
IN8bio, Inc
Via
GlobeNewswire
Tickers
INAB
IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024
April 09, 2024
From
IN8bio, Inc
Via
GlobeNewswire
Tickers
INAB
IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
March 14, 2024
From
IN8bio, Inc
Via
GlobeNewswire
Tickers
INAB
